Refractory cardiac arrest caused by type I Kounis syndrome treated with adrenaline and nicorandil: A case report

Rationale: Kounis syndrome is a rare but life-threatening anaphylactic reaction that can lead to acute coronary syndrome and cardiac arrest, and requires prompt diagnosis. Adrenaline, which is used to treat anaphylaxis, may cause coronary vasoconstriction and worsen ischemia, whereas coronary vasodilators may dilate systemic vessels and exacerbate hypotension. Delayed diagnosis of Kounis syndrome and inadequate therapeutic intervention may thus lead to a poor outcome. Patient concerns: A 59-year-old man was treated for sepsis due to a liver abscess. Following administration of daptomycin, the patient developed severe anaphylactic shock leading to refractory cardiac arrest. Because conventional cardiopulmonary resuscitation was ineffective, extracorporeal cardiopulmonary resuscitation was considered as an alternative approach. Diagnoses: On bedside monitoring during cardiopulmonary resuscitation, unexpected ST-segment elevation was found on lead II electrocardiogram. Accordingly, the patient was clinically diagnosed with Kounis syndrome. Interventions: Nicorandil (6 mg/h), a coronary vasodilator with minimal blood pressure effects, was administered along with high doses of vasopressors, including adrenaline 0.2 µg/kg/min. Outcomes: After the initiation of nicorandil administration, the patient achieved return of spontaneous circulation and did not require extracorporeal cardiopulmonary resuscitation. Based on the elevated serum tryptase level, normal creatine kinase-MB range, and lack of stenosis on coronary angiography, the patient was definitively diagnosed with type I (coronary vasospasm) Kounis syndrome. He was subsequently transferred to the referring hospital without neurological sequelae. Lessons: If anaphylaxis leads to refractory shock and cardiac arrest, ischemic changes on the electrocardiogram should be investigated to identify underlying Kounis syndrome. In addition to adrenaline, coronary dilators are the definitive treatment. Nicorandil may be a useful treatment option because of its minimal effect on blood pressure.

[1]  Hao Zhou,et al.  Effects of Nicorandil Administration on Infarct Size in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial , 2022, Journal of the American Heart Association.

[2]  W. Kim,et al.  Cardiac arrest caused by anaphylaxis refractory to prompt management: A case series and review of the literature. , 2022, The American journal of emergency medicine.

[3]  Peng Liu,et al.  A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020) , 2022, Frontiers in Pharmacology.

[4]  U. Gurunathan,et al.  Perioperative Presentations of Kounis Syndrome: A Systematic Literature Review. , 2022, Journal of cardiothoracic and vascular anesthesia.

[5]  T. Takazawa,et al.  Practical guidelines for the response to perioperative anaphylaxis , 2021, Journal of Anesthesia.

[6]  Motohiro Sekino,et al.  Anaphylactic shock in a patient with severe aortic stenosis treated with adrenaline and landiolol for circulatory management , 2021, Medicine.

[7]  A. Muraro,et al.  EAACI guidelines: Anaphylaxis (2021 update) , 2021, Allergy.

[8]  A. Sheikh,et al.  World allergy organization anaphylaxis guidance 2020 , 2020, The World Allergy Organization journal.

[9]  Motohiro Sekino,et al.  Allergen-Related Coronary Vasospasm "Kounis Syndrome" Requiring Administration of Epinephrine and a Coronary Vasodilator. , 2020, Journal of cardiothoracic and vascular anesthesia.

[10]  M. Bilò,et al.  Fatal anaphylaxis in Italy: Analysis of cause‐of‐death national data, 2004‐2016 , 2020, Allergy.

[11]  K. Ariyoshi,et al.  Two Cardiac Arrests that Occurred after the Administration of Sugammadex: A Case of Kounis Syndrome , 2020, Case reports in emergency medicine.

[12]  A. Kuriyama,et al.  A potential association between myocardial ischemia and epinephrine for anaphylaxis: A case report and literature review. , 2020, The American journal of emergency medicine.

[13]  R. Sachdeva,et al.  Epidemiology of acute coronary syndrome co-existent with allergic/hypersensitivity/anaphylactic reactions (Kounis syndrome) in the United States: A nationwide inpatient analysis. , 2019, International journal of cardiology.

[14]  T. Arai,et al.  A case of Kounis syndrome presenting as coronary artery spasm associated with cefazolin-induced anaphylaxis during general anesthesia , 2019, JA Clinical Reports.

[15]  D. Hepner,et al.  Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations. , 2019, British journal of anaesthesia.

[16]  Y. Nojima,et al.  Kounis syndrome caused by anaphylaxis without skin manifestations after cefazolin administration. , 2019, The journal of allergy and clinical immunology. In practice.

[17]  Y. Matsuki,et al.  A suspected case of coronary vasospasm induced by anaphylactic shock caused by rocuronium-sugammadex complex. , 2018, Journal of clinical anesthesia.

[18]  D. Campbell,et al.  Fatal Anaphylaxis: Mortality Rate and Risk Factors , 2017, The journal of allergy and clinical immunology. In practice.

[19]  R. Subedi,et al.  Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome. , 2017, International journal of cardiology.

[20]  N. Kounis Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management , 2016, Clinical chemistry and laboratory medicine.

[21]  S. Sakamoto,et al.  Successful treatment of prolonged cardiopulmonary arrest of Kounis syndrome during coronary angioplasty. , 2016, Journal of cardiology cases.

[22]  Mathias Wilhelms,et al.  ECG-Based Detection of Early Myocardial Ischemia in a Computational Model: Impact of Additional Electrodes, Optimal Placement, and a New Feature for ST Deviation , 2015, BioMed research international.

[23]  C. Camargo,et al.  Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. , 2014, The Journal of allergy and clinical immunology.

[24]  L. Borish,et al.  Case fatality and population mortality associated with anaphylaxis in the United States. , 2014, The Journal of allergy and clinical immunology.

[25]  T. Katagiri,et al.  Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. , 2010, Journal of cardiology.

[26]  N. Hagiwara,et al.  Acute Efficacy and Safety of Intravenous Administration of Nicorandil in Patients With Acute Heart Failure Syndromes: Usefulness of Noninvasive Echocardiographic Hemodynamic Evaluation , 2009, Journal of cardiovascular pharmacology.

[27]  R. Lockey,et al.  Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization , 2008, Allergy.

[28]  R. Lockey,et al.  Epinephrine: The Drug of Choice for Anaphylaxis--A Statement of the World Allergy Organization , 2008, The World Allergy Organization journal.

[29]  John Launer Supervision , 2008, Postgraduate Medical Journal.

[30]  M. Kinoshita,et al.  Effects of intravenous nicorandil on coronary circulation in humans: plasma concentration and action mechanism. , 2000, Journal of cardiovascular pharmacology.

[31]  M. Kucukoglu,et al.  Investigation , 2000, BMJ : British Medical Journal.

[32]  H. Yasue,et al.  Prinzmetal's variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: documentation by coronary arteriography. , 1976, American heart journal.

[33]  Norma Banas,et al.  Virtual Reality Visualization of 3-D Electromagnetic Fields , 2000 .